Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.45), $0.12 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $459 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.